Table 2. Patient Dosing and DLT Assessment.

Dose Cohort	ABT-888 (mg days 5-21 of cycle 1 and 1-21 of subsequent cycles)	XRT (cGy days 1 and 5 weeks 1-3 for 3 cycles*)	N	Median no of Completed Cycles (range)	DLT
1	40mg BID	60 cGy	3	2.66 (2-3)	0
2	80mg BID	60 cGy	6	2.16 (0-3)	**1
3	120mg BID	60 cGy	6	2.00 (1-3)	0
4	160mg BID	60 cGy	7	1.71 (1-3)	0

^*Cycle is 28 days

^**Grade 2, protracted thrombocytopenia. By the original protocol, this would not have met requirement for DLT. However, this was considered a DLT at the discretion of the principle investigators.